TY - JOUR
T1 - EDTA as an adjunct antifungal agent for invasive pulmonary aspergillosis in a rodent model
AU - Hachem, Ray
AU - Bahna, Paul
AU - Hanna, Hend
AU - Stephens, L. Clifton
AU - Raad, Issam
PY - 2006/5
Y1 - 2006/5
N2 - Rats immunosuppressed by the administration of cyclophosphamide and cortisone acetate and then infected with Aspergillus fumigatus were treated with an antifungal drug, EDTA, or a combination of one of the antifungal agents, amphotericin B lipid complex (ABLC; 5 mg/kg of body weight/day for 7 days), and EDTA (30 mg/kg/day for 7 days). The mortality rate was reduced, the duration of survival was increased, fewer A. fumigatus organisms were recovered from the lungs, and less-severe lung lesions were seen histopathologically in the rats receiving the combination treatment than in the rats receiving either an antifungal agent or EDTA alone. Further studies regarding the mechanisms of EDTA and its interactions with ABLC are warranted, and further studies are needed to more fully examine the safety, tolerance, and optimal dosing of EDTA in the treatment of this and other fungal infections.
AB - Rats immunosuppressed by the administration of cyclophosphamide and cortisone acetate and then infected with Aspergillus fumigatus were treated with an antifungal drug, EDTA, or a combination of one of the antifungal agents, amphotericin B lipid complex (ABLC; 5 mg/kg of body weight/day for 7 days), and EDTA (30 mg/kg/day for 7 days). The mortality rate was reduced, the duration of survival was increased, fewer A. fumigatus organisms were recovered from the lungs, and less-severe lung lesions were seen histopathologically in the rats receiving the combination treatment than in the rats receiving either an antifungal agent or EDTA alone. Further studies regarding the mechanisms of EDTA and its interactions with ABLC are warranted, and further studies are needed to more fully examine the safety, tolerance, and optimal dosing of EDTA in the treatment of this and other fungal infections.
UR - http://www.scopus.com/inward/record.url?scp=33646445592&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=33646445592&partnerID=8YFLogxK
U2 - 10.1128/AAC.50.5.1823-1827.2006
DO - 10.1128/AAC.50.5.1823-1827.2006
M3 - Article
C2 - 16641455
AN - SCOPUS:33646445592
SN - 0066-4804
VL - 50
SP - 1823
EP - 1827
JO - Antimicrobial agents and chemotherapy
JF - Antimicrobial agents and chemotherapy
IS - 5
ER -